Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons

NeuroReport

Volumn 14, Issue 3, 2003, Pages 471-475

  Ängehagen, Mikael ^a   Margineanu, Doru Georg ^b   Ben Menachem, Elinor ^a   Rönnbäck, Lars ^a   Hansson, Elisabeth ^a   Klitgaard, Henrik ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UCB PHARMA   (Belgium)

Author keywords

Calcium imaging; Field potentials; Hippocampal neurons; Levetiracetam; ucb L060

Indexed keywords

CAFFEINE; ETIRACETAM; UCB L 060; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN SLICE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ELECTRIC POTENTIAL; EPILEPTIC DISCHARGE; EVOKED RESPONSE; EXCITATION; HIPPOCAMPUS; MOLECULAR MECHANICS; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH ENDOPLASMIC RETICULUM; SPIKE;

ANIMALS; ANTICONVULSANTS; CAFFEINE; CALCIUM; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROPHYSIOLOGY; EPILEPSY; HIPPOCAMPUS; NEURONS; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0345700624     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ben-Menachem E and Falter U. Epilepsia 41, 1276-1283 (2000).
2. Cereghino JJ, Biton V, Abou-Khalil B et al. Neurology 55, 236-242 (2000).
3. Marson AG, Hutton JL, Leach JP et al. Epilepsy Res 46, 259-270 (2001).
4. Klitgaard H, Matagne A, Gobert J et al. Eur J Pharmacol 353, 191-206 (1998).
5. Klitgaard H. Epilepsia 42 (Suppl. 4), 13-18 (2001).
6. Noyer M, Gillard M, Matagne A et al. Eur J Pharmacol 286, 137-146 (1995).
7. Margineanu DG and Klitgaard H. Levetiracetam: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS et al. (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams and Wilkins; 2002, pp. 419-427.
8. Margineanu DG and Wülfert E. Br J Pharmacol 122, 1146-1150 (1997).
9. Niespodziany I, Klitgaard H and Margineanu DG. Neurosci Lett 306, 5-8 (2001).
10. Lukyanetz EA, Shkryl VM and Kostyuk PG. Epilepsia 43, 9-18 (2002).
11. Wülfert E and Margineanu DG. Neurosci Lett 243, 141-143 (1998).
12. Usachev Y, Shmigol A, Pronchuk N et al. Neuroscience 57, 845-859 (1993).
13. Ängehagen M, Margineanu DG, Rönnbäck L et al. Epilepsia 43 (Suppl. 7), 99 (2002).
14. Nilsson M, Hansson E and Rönnbäck L. Brain Res Dev Brain Res 63, 33-41 (1991).
15. Hansson E. Prog Neurobiol 30, 369-397 (1988).
16. Pettmann B, Louis JC and Sensenbrenner M. Nature 281, 378-380 (1979).
17. Blomstrand F, Khatibi S, Muyderman H et al. Neuroscience 88, 1241-1253 (1999).
18. Nilsson M, Eriksson PS, Rönnbäck L et al. Neuroscience 54, 605-614 (1993).
19. Kolchegarov AA, Beylina SI, Matveeva NB et al. Biochemistry (Moscow) 65, 662-671 (2000).
20. Margineanu DG and Klitgaard H. Neuropharmacology 41, 377-383 (2001).
21. Belousov AB, Godfraind JM and Krnjevic K. J Physiol 486, 547-556 (1995).
22. Desaulles E, Boux O and Feltz P. Eur J Pharmacol 203, 137-140 (1991).
23. De Koninck Y and Mody I. Neuropharmacology 35, 1365-1374 (1996).
24. Moraidis I, Bingmann D, Lehmenkuhler A et al. Neurosci Lett 129, 51-54 (1991).
25. Serafin WE. Drugs used in the treatment of asthma. In: Hardman JG and Limbird LE (eds in chief). Goodman and Gilman's Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill; 1996, pp. 659-682.
26. Albowitz B, Konig P and Kuhnt U. J Neurophysiol 77, 491-501 (1997).
27. Segal M and Manor D. J Physiol 448, 655-676 (1992).